UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Part of paid clinical trials in Detroit, Michigan.

Sponsor
David Lanfear
Study ID
NCT07054489
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • Beta blocker — OTHER
    Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.

Study Details

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Key Dates

Start date
Mar 30, 2026
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Beta Blocker
    This group will be dispensed and titrated on beta blocker according to study protocol.
  • No Intervention: Placebo
    This group will be dispensed and titrated on placebo according to study protocol.

Primary Outcome Measure

Change in left ventricle end systolic volume index [ Time Frame: Within 6 months of randomization ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry Ford HealthDetroitMichigan48202
Whitney Cabral
[email protected]
313-949-6616

Find similar trials in Detroit, MI

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Henry Ford Health· Detroit, MI

Related Studies